Erin Furr-Stimming, MD
Neurology · Houston, TXNPI 1477749216
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.1%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by PTC Therapeutics, Inc. at 24.2% of the total. Reporting peaked in 2024 at $14,580 and has fallen 81.8% since, to $2,659 in 2025. Among neurology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 368 payments — averaging $153.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- PTC Therapeutics, Inc.$14K
- Teva Pharmaceuticals USA, Inc.$13K
- Neurocrine Biosciences, Inc.$7K
- Sunovion Pharmaceuticals Inc.$6K
- F. Hoffmann-la Roche AG$5K
- Novartis$4K
- plus $9K from 24 others
Across 91 payments — averaging $23,028 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.3M
- Sage Therapeutics, LLC$495K
- F. Hoffmann-la Roche AG$169K
- Neurocrine Biosciences, Inc.$104K
- PTC Therapeutics, Inc.$20K
What the payments were for
- Consulting fees$30,05753%
- Speaking & faculty fees$7,46013%
- Travel & lodging$10,60119%
- Food & beverage$8,35915%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| PTC Therapeutics, Inc. | 27 | $13,714 |
| Teva Pharmaceuticals USA, Inc. | 50 | $13,273 |
| Neurocrine Biosciences, Inc. | 18 | $6,610 |
| Sunovion Pharmaceuticals Inc. | 16 | $5,726 |
| F. Hoffmann-la Roche AG | 5 | $5,115 |
| Novartis | 3 | $3,601 |
| Amneal Pharmaceuticals LLC | 16 | $2,547 |
| AbbVie(2 entities) | 80 | $1,476 |
| Medtronic(2 entities) | 26 | $1,403 |
| Abbott | 42 | $951 |
| Acadia Pharmaceuticals Inc | 25 | $478 |
| Acorda Therapeutics, Inc | 12 | $355 |
| Supernus Pharmaceuticals, Inc. | 8 | $163 |
| Boston Scientific | 2 | $139 |
| SK Life Science, Inc. | 2 | $134 |
| UCB, Inc. | 5 | $109 |
| Azurity Pharmaceuticals, Inc. | 1 | $108 |
| Biogen | 5 | $103 |
| Merz Pharmaceuticals, LLC | 5 | $92 |
| MDD US Operations, LLC | 4 | $92 |
| Genentech USA, Inc. | 1 | $91 |
| Adamas Pharmaceuticals, Inc. | 3 | $71 |
| Kyowa Kirin, Inc. | 2 | $45 |
| Avion Pharmaceuticals | 2 | $41 |
| EMD Serono, Inc. | 1 | $29 |
| Insightec,inc | 3 | $26 |
| Merz North America, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$8,951
- KYNMOBI$5,500
- Non-Covered Product$5,040
- Austedo XR$3,563
- RYTARY$2,158
- PERCEPT PC BRAINSENSE$469
- ACTIVA PC$268
- INFINITY$260
- NUPLAZID$124
- VYALEV$122
- CREXONT$115
- VERCISE$112
- Horizant$108
- INBRIJA$103
How this compares
$56,578 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 84 | $934,957 |
| IngrezzaValbenazine Tosylate | 89 | $835,738 |
| Austedo XrDeutetrabenazine | 58 | $623,853 |
| NuplazidPimavanserin Tartrate | 35 | $215,459 |
| RytaryCarbidopa/Levodopa | 158 | $182,811 |
| GocovriAmantadine Hcl | 50 | $108,726 |
| InbrijaLevodopa | 16 | $62,388 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $15,277 |
| BotoxOnabotulinumtoxina | 13 | $7,982 |
| Rivastigmine | 23 | $4,123 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 139 | $3,603 |
| XeominIncobotulinumtoxina | 11 | $3,398 |
| RivastigmineRivastigmine Tartrate | 63 | $2,700 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 88 | $2,097 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 11 | $2,090 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $13,273 | $1,558,809142 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $6,610 | $835,73889 claims |
| Acadia Pharmaceuticals IncNuplazid | $478 | $215,45935 claims |
| Amneal Pharmaceuticals LLCRytary | $2,547 | $182,811158 claims |
| MDD US Operations, LLCGocovri | $92 | $108,72650 claims |
| Acorda Therapeutics, IncInbrija | $355 | $62,38816 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $18 | $15,27711 claims |
| AbbVieBotox | $1,476 | $7,98213 claims |
| Merz North America, Inc.Xeomin | $25 | $3,39811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.
Other neurology in Houston
- William OndoHouston$1.4M
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Randolph EvansHouston$493K
- Leorah FreemanHouston$401K
- Mazen DimachkieHouston$388K
- Zsila SadighiHouston$361K
- Joseph JankovicHouston$323K
- Raja MehannaHouston$300K
- Eddie PattonHouston$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.